~ Buy the JESDUVROQ (daprodustat) Drug Profile, 2024 PDF Report in the Report Store ~

JESDUVROQ Drug Patent Profile

Which patents cover Jesduvroq, and when can generic versions of Jesduvroq launch?

Jesduvroq is a drug marketed by Glaxosmithkline and is included in one NDA. There are six patents protecting this drug.

This drug has forty-two patent family members in thirty-one countries.

The generic ingredient in JESDUVROQ is daprodustat. One supplier is listed for this compound. Additional details are available on the daprodustat profile page.

DrugPatentWatch^® Generic Entry Outlook for Jesduvroq

Jesduvroq will be eligible for patent challenges on February 1, 2027. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be February 1, 2028. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for JESDUVROQ

International Patents:	42
US Patents:	6
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	46
Patent Applications:	19
Drug Prices:	Drug price information for JESDUVROQ
What excipients (inactive ingredients) are in JESDUVROQ?	JESDUVROQ excipients list
DailyMed Link:	JESDUVROQ at DailyMed

See drug prices for JESDUVROQ

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for JESDUVROQ

Constraining patent/regulatory exclusivity:

NEW CHEMICAL ENTITY

NDA:

216951

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Anatomical Therapeutic Chemical (ATC) Classes for JESDUVROQ

B03XA	Other antianemic preparations
B03X	OTHER ANTIANEMIC PREPARATIONS
B03	ANTIANEMIC PREPARATIONS
B	Blood and blood forming organs

US Patents and Regulatory Information for JESDUVROQ

JESDUVROQ is protected by six US patents and one FDA Regulatory Exclusivity.

This potential generic entry date is based on NEW CHEMICAL ENTITY.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting JESDUVROQ

FDA Regulatory Exclusivity protecting JESDUVROQ

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxosmithkline	JESDUVROQ	daprodustat	TABLET;ORAL	216951-005	Feb 1, 2023		RX	Yes	Yes			Y
Glaxosmithkline	JESDUVROQ	daprodustat	TABLET;ORAL	216951-004	Feb 1, 2023		RX	Yes	No
Glaxosmithkline	JESDUVROQ	daprodustat	TABLET;ORAL	216951-005	Feb 1, 2023		RX	Yes	Yes				Y
Glaxosmithkline	JESDUVROQ	daprodustat	TABLET;ORAL	216951-005	Feb 1, 2023		RX	Yes	Yes			Y	Y
Glaxosmithkline	JESDUVROQ	daprodustat	TABLET;ORAL	216951-001	Feb 1, 2023		RX	Yes	No			Y	Y
Glaxosmithkline	JESDUVROQ	daprodustat	TABLET;ORAL	216951-003	Feb 1, 2023		RX	Yes	No			Y

International Patents for JESDUVROQ

See the table below for patents covering JESDUVROQ around the world.

Country	Patent Number	Title	Estimated Expiration
China	111093668	GSK1278863 的晶型及其制备方法和制药用途 (CRYSTAL FORM OF GSK1278863 AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF)
World Intellectual Property Organization (WIPO)	2007150011
Taiwan	I394747
Croatia	P20140306
Morocco	30526	INHIBITEURS DE PROLYLE HYDROXYLASE
Eurasian Patent Organization	018220	ИНГИБИТОРЫ ПРОЛИЛГИДРОКСИЛАЗ (PROLYL HYDROXYLASE INHIBITORS)